We narrowed to 569 results for: uros

#107712-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin-FLEX-soCoChR-GFP (#107712). In addition to the viral particles, you will also receive purified pAAV-hSynapsin-FLEX-soCoChR-GFP plasmid DNA. Synapsin-driven, Cre-dependent somatic CoChR (soCoChR) fused to GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Shemesh et al Nat Neurosci. 2017 Dec;20(12):1796-1806.

Sept. 7, 2018

Academic Institutions and Nonprofits only

#45580-AAV1

Ready-to-use AAV1 particles produced from pAAV-flex-taCasp3-TEVp (#45580). In addition to the viral particles, you will also receive purified pAAV-flex-taCasp3-TEVp plasmid DNA. EF1a-driven, Cre-dependent, bicicstronic expression of designer pro-taCasp3 and TEVp. These AAV preparations are suitable purity for injection into animals.

Nirao Shah, Jim Wells

Yang et al Cell. 2013 May 9;153(4):896-909. doi: 10

Dec. 3, 2020

Academic Institutions and Nonprofits only

#84471-AAV8

Ready-to-use AAV8 particles produced from pAAV-RAM-d2TTA::TRE-ChR2-WPREpA (#84471). In addition to the viral particles, you will also receive purified pAAV-RAM-d2TTA::TRE-ChR2-WPREpA plasmid DNA. RAM-containing and TRE-driven, ChR2 H134R mutant fused to EYFP. These AAV preparations are suitable purity for injection into animals.

Yingxi Lin

Sorensen et al Elife. 2016 Sep 23;5. pii: e13918. doi:

Jan. 15, 2026

Academic Institutions and Nonprofits only

#111068-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn-dLight1.2 (#111068). In addition to the viral particles, you will also receive purified pAAV-hSyn-dLight1.2 plasmid DNA. Synapsin-driven expression of dLight1.2 dopamine sensor. This sensor has a slightly increased dynamic range and is better for 2P imaging in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Dec. 14, 2018

Academic Institutions and Nonprofits only

#111067-AAV5

Ready-to-use AAV5 particles produced from pAAV-CAG-dLight1.1 (#111067). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.1 plasmid DNA. CAG-driven expression of dLight1.1 dopamine sensor. This sensor is recommended for photometry in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Dec. 14, 2018

Academic Institutions and Nonprofits only

#52473-AAV1

Ready-to-use AAV1 particles produced from pAAV-synP-FLEX-splitTVA-EGFP-B19G (#52473). In addition to the viral particles, you will also receive purified pAAV-synP-FLEX-splitTVA-EGFP-B19G plasmid DNA. Helper virus for monosynaptic tracing with rabies virus. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

Kohara et al Nat Neurosci. 2014 Feb;17(2):269-79. doi

Dec. 18, 2018

Academic Institutions and Nonprofits only

#112005-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 (#112005). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and mRuby3 expression. The mRuby3 will be a separate protein (not a fusion protein). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Dec. 4, 2018

Academic Institutions and Nonprofits only

#111068-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-dLight1.2 (#111068). In addition to the viral particles, you will also receive purified pAAV-hSyn-dLight1.2 plasmid DNA. Synapsin-driven expression of dLight1.2 dopamine sensor. This sensor has a slightly increased dynamic range and is better for 2P imaging in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

Feb. 25, 2021

Academic Institutions and Nonprofits only

#112005-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 (#112005). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mRuby3 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and mRuby3 expression. The mRuby3 will be a separate protein (not a fusion protein). These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

April 24, 2019

Academic Institutions and Nonprofits only

#169128-AAV1

Ready-to-use AAV1 particles produced from pAAV-DIO-EF1α-mKate2-PDE4D3-Cat (#169128). In addition to the viral particles, you will also receive purified pAAV-DIO-EF1α-mKate2-PDE4D3-Cat plasmid DNA. EF1a-driven, Cre-dependent expression of truncated PDE4D3 and mKate2. These AAV preparations are suitable purity for injection into animals.

Georg Nagel

Zhang et al Nature. 2021 Sep;597(7875):245-249. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#99130-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-mDlx-NLS-mRuby2 (#99130). In addition to the viral particles, you will also receive purified pAAV-mDlx-NLS-mRuby2 plasmid DNA. mDlx-driven NLS-mRuby2 expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Chan et al Nat Neurosci. 2017 Aug;20(8):1172-1179.

Feb. 16, 2024

Academic Institutions and Nonprofits only

#111067-AAV1

Ready-to-use AAV1 particles produced from pAAV-CAG-dLight1.1 (#111067). In addition to the viral particles, you will also receive purified pAAV-CAG-dLight1.1 plasmid DNA. CAG-driven expression of dLight1.1 dopamine sensor. This sensor is recommended for photometry in vivo. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Patriarchi et al Science. 2018 Jun 29;360(6396). pii: sci

March 12, 2021

Academic Institutions and Nonprofits only

#69571-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-C-CreintG (#69571). In addition to the viral particles, you will also receive purified pAAV-EF1a-C-CreintG plasmid DNA. EF1a-driven expression of optimized C-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-N-CretrcintG (Addgene catalog# 69570) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#69570-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-N-CretrcintG (#69570). In addition to the viral particles, you will also receive purified pAAV-EF1a-N-CretrcintG plasmid DNA. EF1a-driven expression of optimized N-terminal component of Cre recombinase dependent on GFP (Cre-DOG OPT); to be coinjected with pAAV-EF1a-C-CreintG (Addgene catalog# 69571) and GFP (or for use with transgenic GFP animals). These AAV preparations are suitable purity for injection into animals.

Connie Cepko

Tang et al Nat Neurosci. 2015 Sep;18(9):1334-41. do

Feb. 19, 2020

Academic Institutions and Nonprofits only

#112004-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 (#112004). In addition to the viral particles, you will also receive purified pAAV-hSynapsin1-axon-GCaMP6s-P2A-mKate2 plasmid DNA. Synapsin-driven, axon-targeted GCaMP6s calcium sensor and bicistronic mKate2 expression. These AAV preparations are suitable purity for injection into animals.

Lin Tian

Broussard et al Nat Neurosci. 2018 Sep;21(9):1272-1280.

Feb. 14, 2022

Academic Institutions and Nonprofits only

#154948-AAV9

Ready-to-use AAV9 particles produced from CaMKII-somBiPOLES-mCerulean (#154948). In addition to the viral particles, you will also receive purified CaMKII-somBiPOLES-mCerulean plasmid DNA. CamKII-driven expression of soma-targeted BiPOLES for optogenetic inhibition (blue light) and activation (red light). These AAV preparations are suitable purity for injection into animals.

Simon Wiegert

Vierock et al Nat Commun. 2021 Jul 26;12(1):4527. doi:

Sept. 1, 2021

Academic Institutions and Nonprofits only

#154948-AAV5

Ready-to-use AAV5 particles produced from CaMKII-somBiPOLES-mCerulean (#154948). In addition to the viral particles, you will also receive purified CaMKII-somBiPOLES-mCerulean plasmid DNA. CamKII-driven expression of soma-targeted BiPOLES for optogenetic inhibition (blue light) and activation (red light). These AAV preparations are suitable purity for injection into animals.

Simon Wiegert

Vierock et al Nat Commun. 2021 Jul 26;12(1):4527. doi:

Sept. 1, 2021

Academic Institutions and Nonprofits only

#232837-AAV8

Ready-to-use AAV8 particles produced from pAAV-Syn-NES-SomaFRCaMPi (#232837). In addition to the viral particles, you will also receive purified pAAV-Syn-NES-SomaFRCaMPi plasmid DNA. Synapsin-driven SomaFRCaMPi calcium sensor. These AAV preparations are suitable purity for injection into animals.

Kiryl Piatkevich

Zhou et al PLoS Biol. 2025 Apr 29;23(4):e3003048. d

Jan. 15, 2026

Academic Institutions and Nonprofits only

#65014-AAV8

Ready-to-use AAV8 particles produced from pAAV-hsyn-Jaws-KGC-GFP-ER2 (#65014). In addition to the viral particles, you will also receive purified pAAV-hsyn-Jaws-KGC-GFP-ER2 plasmid DNA. hSyn-driven Jaws-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chuong et al Nat Neurosci. 2014 Aug;17(8):1123-9. doi

Oct. 13, 2017

Academic Institutions and Nonprofits only

#107312-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-mCherry-P2A-Cre-WPRE (#107312). In addition to the viral particles, you will also receive purified AAV-hSyn-mCherry-P2A-Cre-WPRE plasmid DNA. hSyn-driven expression of mCherry and Cre (physically separate). These AAV preparations are suitable purity for injection into animals.

Hui Yang

Zhou et al Nat Neurosci. 2018 Jan 15. pii: 10.1038/

Oct. 28, 2021

Academic Institutions and Nonprofits only